Komipharm International Co Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

9.11

EPS

—

Div Yield, %

—

Shrs. gr., 5y

0.98%

Rev. gr., 5y

7.14%

Revenues

52.47b

-10.74%

Net income

-7.21b

CFO

-622m

Dividend

Dec 29, 20033.3284 KRW/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Profile

Komipharm International Co., Ltd. is a South Korean biopharmaceutical firm specializing in the research, development, and production of veterinary pharmaceuticals and animal vaccines. Their extensive portfolio features vaccines designed for livestock like swine, cattle, and poultry, as well as companion animals such as canines. Complementing these, they offer antibiotics, disinfectants, and bio-fertilizers, in addition to providing clinical laboratory services. The company is also expanding its focus to human health, with ongoing development of anticancer drugs and pain management agents.

URL

http://www.komipharm.com/

IPO date

Oct 30, 2001

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT